Deep Track discloses 0.40% stake in RAPT
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RAPT Therapeutics, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 110,448 shares of common stock, representing 0.40% of the class as of December 31, 2025.
The reporting persons have shared voting and dispositive power over all 110,448 shares and no sole power. The percentage is based on 27,710,871 shares outstanding as of November 3, 2025, as disclosed in the issuer’s Form 10-Q. They certify the holdings are not for the purpose of changing or influencing control of RAPT.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does Deep Track report in RAPT (RAPT)?
How was the 0.40% ownership in RAPT (RAPT) calculated?
Who are the reporting persons in this RAPT (RAPT) Schedule 13G/A?
Does Deep Track seek control of RAPT (RAPT) through this stake?
What does ‘ownership of 5 percent or less’ mean for RAPT (RAPT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.